Drospirenone, Ethinyl Estradiol And Levomefolate Calcium And Levomefolate Calcium Kit
NDC 68180-894

View dosage, usage, ingredients, routes, and UNII mappings.
Table of Contents
  1. Product Information
  2. Product Packages
  3. Product Characteristics
  4. What is NDC 68180-894?
  5. Drospirenone, Ethinyl Estradiol And Levomefolate Calcium And Levomefolate Calcium Uses
  6. Active Ingredients UNII Codes
  7. Inactive Ingredients UNII Codes
  8. NDC to RxNorm Crosswalk
  9. Patient Education

Product Information

Drospirenone, Ethinyl Estradiol And Levomefolate Calcium And Levomefolate Calcium is a ANDA-approved product labeled by Lupin Pharmaceuticals, Inc.. This product is primarily utilized in pharmaceutical processing or compounding. It is supplied as a pink kit. This product entry covers the primary NDC 68180-894 and 2 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.

Primary Identification

NDC Product Code:
68180-894
Proprietary Name:
Drospirenone, Ethinyl Estradiol And Levomefolate Calcium And Levomefolate Calcium
Non-Proprietary Name: [1]
Drospirenone, Ethinyl Estradiol And Levomefolate Calcium And Levomefolate Calcium
NDC Directory Status:
Human Prescription Drug
Product Type: [3]
ACTIVE PRODUCT INCLUDED in the NDC Directory
Code Navigator:

Clinical Specifications

Dosage Form:
Kit - A packaged collection of related material.

Labeler & Regulatory Data

Labeler Name: [5]
Lupin Pharmaceuticals, Inc.
Labeler Code:
68180
Product Label ID:
48f4301c-0426-43cd-af37-c4d8fc7aeb67
FDA Application Number: [6]
ANDA205947
Marketing Category: [8]
ANDA - A product marketed under an approved Abbreviated New Drug Application.

Marketing Timeline

Start Marketing Date: [9]
08-22-2018
Listing Expiration Date: [11]
12-31-2026
Exclude Flag: [12]
N

Product Characteristics

Color(s):
PINK (C48328)
ORANGE (C48331 - LIGHT ORANGE)
Shape:
ROUND (C48348)
Size(s):
6 MM
Imprint(s):
LU;J61
LU;J62
Score:
1

Code Structure Chart

Product Details

What is NDC 68180-894?

The NDC code 68180-894 is assigned by the FDA to the product Drospirenone, Ethinyl Estradiol And Levomefolate Calcium And Levomefolate Calcium. This pharmaceutical product is labeled by Lupin Pharmaceuticals, Inc. and is currently categorized as listed product. The medication is a kit. In terms of distribution, this product is available in 2 different package configurations. The associated package NDC(s) include: 68180-894-13, 68180-894-73. Beyond standard identification, this entry provides technical data including pharmacologic classes, UNII ingredient references, and RxNorm cross-referencing for healthcare systems.

What are the uses of this product?

Drospirenone, ethinyl estradiol and levomefolate calcium tablet and levomefolate calcium tablet is contraindicated in females who are known to have or develop the following conditions:Renal impairmentAdrenal insufficiencyA high risk of arterial or venous thrombotic diseases. Examples include women who are known to:Smoke, if over age 35 [see Boxed Warning and Warnings And Precautions (5.1)]Have deep vein thrombosis or pulmonary embolism, now or in the past [see Warnings And Precautions (5.1)]Have cerebrovascular disease[see Warnings And Precautions (5.1)]Have coronary artery disease[see Warnings And Precautions (5.1)]Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see Warnings And Precautions (5.1)]Have inherited or acquired hypercoagulopathies [see Warnings And Precautions (5.1)]Have uncontrolled hypertension [see Warnings And Precautions (5.6)]Have diabetes mellitus with vascular disease [see Warnings And Precautions (5.8)]Have headaches with focal neurological symptoms or have migraine headaches with or without aura if over age 35 [see Warnings And Precautions (5.9)]Undiagnosed abnormal uterine bleeding [see Warnings And Precautions (5.10)]Current diagnosis of, or history of, breast cancer, which may be hormone-sensitive [see Warnings And Precautions (5.3)]Liver tumors, benign or malignant, or liver disease [see Warnings And Precautions (5.4) and Use In Specific Populations (8.7)]Pregnancy, because there is no reason to use COCs during pregnancy [see Warnings And Precautions (5.11) and Use In Specific Populations (8.1)]Use of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir due to the potential for ALT elevations [see Warnings And Precautions (5.5) and Drug Interactions (7.3)].

Which are the associated UNII Codes?

The UNII codes for the active ingredients in this product are:

Which are the Inactive Ingredients associated UNII Codes?

The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:

What is the NDC to RxNorm Crosswalk for this product?

RxNorm is a normalized naming system for generic and branded drugs that assigns unique concept identifier(s) known as RxCUIs to NDC products.The NDC to RxNorm Crosswalk for this produdct indicates multiple concept unique identifiers (RXCUIs) are associated with this product:
  • RxCUI: 1013626 - drospirenone 3 MG / ethinyl estradiol 0.02 MG / levomefolate calcium 0.451 MG Oral Tablet
  • RxCUI: 1013628 - levomefolate calcium 0.451 MG Oral Tablet
  • RxCUI: 1013629 - {24 (drospirenone 3 MG / ethinyl estradiol 0.02 MG / levomefolate calcium 0.451 MG Oral Tablet) / 4 (levomefolate calcium 0.451 MG Oral Tablet) } Pack
  • RxCUI: 1013629 - Drospiren-Eth estra-Levomefol Ca 3-0.02-0.451 MG (24) Oral Tablet / Levomefol Ca 0.451 MG (4) Oral Tablet 28 Day Pack

* Please review the full disclaimer at the bottom of this page.

Patient Education

Estrogen and Progestin (Oral Contraceptives)


Oral contraceptives (birth-control pills) are used to prevent pregnancy. Estrogen and progestin are two female sex hormones. Combinations of estrogen and progestin work by preventing ovulation (the release of eggs from the ovaries). They also change the lining of the uterus (womb) to prevent pregnancy from developing and change the mucus at the cervix (opening of the uterus) to prevent sperm (male reproductive cells) from entering. Oral contraceptives are a very effective method of birth control, but they do not prevent the spread of human immunodeficiency virus (HIV, the virus that causes acquired immunodeficiency syndrome [AIDS]) and other sexually transmitted diseases. Some brands of oral contraceptives are also used to treat acne in certain patients. Oral contraceptives treat acne by decreasing the amounts of certain natural substances that can cause acne. Some oral contraceptives (Beyaz, Yaz) are also used to relieve the symptoms of premenstrual dysphoric disorder (physical and emotional symptoms that occur before the menstrual period each month) in women who have chosen to use an oral contraceptive to prevent pregnancy.
[Learn More]


* Please review the full disclaimer at the bottom of this page.

Product & Regulatory Definitions
What is the Non-Proprietary Name? The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.
What kind of product is this? Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.
What is the Labeler Name? Name of Company corresponding to the labeler code segment of the Product NDC.
What is the FDA Application Number? This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
What is the Marketing Category? Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
What is the Start Marketing Date? This is the date that the labeler indicates was the start of its marketing of the drug product.
What is the Listing Expiration Date? This is the date when the listing record will expire if not updated or certified by the product labeler.
What is the NDC Exclude Flag? This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA"s requests for correction to deficient or non-compliant submissions, or because the listing certification is expired, or because the listing data was inactivated by FDA, or because it was discontinued by the labeler. Possible values in this field are: "D", "E", "I", "N", "U".